Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Harbour BioMed Partner, Solstice Oncology

Harbour BioMed Partner, Solstice Oncology

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$225Msum of rounds with a disclosed amount only
Named investors
3
Financing history
1 rounds
  1. Sep 9, 2026
    Series A · $225M (disclosed)
    RA Capital Management, LP (lead)Canaan Partners (participant)Forbion (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy”
Investors on record
3 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Sep 9, 2026
    Harbour BioMed Partner, Solstice Oncology announced Series A of $225,000,000, led by RA Capital Management
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company